Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
IPO Year: 2004
Exchange: NASDAQ
Website: corcept.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2023 | $29.00 → $38.00 | Hold → Buy | Truist |
| 4/11/2023 | $25.00 | Market Perform | SVB Securities |
| 4/4/2023 | $27.00 | Overweight | Piper Sandler |
| 2/15/2023 | $35.00 → $22.00 | Buy → Hold | Jefferies |
| 8/1/2022 | $30.00 | Buy → Hold | Truist |
| 7/27/2022 | $21.00 → $35.00 | Hold → Buy | Jefferies |
| 6/27/2022 | $30.00 → $34.00 | Buy | Canaccord Genuity |
| 2/2/2022 | $30.00 | Buy | Canaccord Genuity |
| 1/28/2022 | $30.00 | Buy | Truist |
| 6/23/2021 | $32.00 → $29.00 | Buy | HC Wainwright & Co. |
5 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company’s Board of Directors. Mr. Murray is currently Senior Vice President, Finance, Strategy and Investor Relations at Orca Bio, a privately held biotechnology company developing allogeneic cell therapies in blood, immune, and genetic diseases. Prior to joining Orca, Mr. Murray spent 15 years at Goldman Sachs, most recently as a Managing
144 - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
144 - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
S-8 POS - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
S-8 POS - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
S-8 POS - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.
Revenue of $182.5 million, a 48 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 Cash and investments of $547.6 million as of September 30, 2024 Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by mod
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutic
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 millionNet income per common share of $0.32 (diluted), compared to $0.25 in second quarter 2023Cash and investments of $492.5 million as of June 30
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Inve
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024. Financial Results Revenue of $146.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $620 – $650 million, from $600 - $630 millionNet income per common share of $0.25 (diluted), compared to $0.14 in first quarter 2023Cash and investments of $451.0 million as of
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Ev
MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be avai
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023. Financial Results Revenue of $123.6 million, a 22 percent increase from third quarter 2022Increase in 2023 revenue guidance to $470 - $480 million, from $455 - $470 million Net income per common share of $0.28 (diluted), compared to $0.30 in third quarter 2022 Cash and investments of $414.8 million as of September 30, 20
MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome). Corcept's NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism. Patients in these
Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) 116 patients with hypercortisolism were enrolled with treatment duration of up to six years Results provide further evidence of relacorilant's potential benefit as a treatment for patients with hypercortisolism Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented r
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes. CATALYST is a prospective, Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1057 patients with difficult-to-control type 2 diabetes, def
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating two doses (150 mg and 300 mg) of its proprietary selective cortisol modulator dazucorilant in patients with ALS. Upon completion of the trial, patients were eligible to enter an open-label, long-term extension study, in which they received 300 mg of dazucorilant. DAZALS did not meet its primary endpoint, which was
Revenue of $182.5 million, a 48 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 Cash and investments of $547.6 million as of September 30, 2024 Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by mod
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutic
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 millionNet income per common share of $0.32 (diluted), compared to $0.25 in second quarter 2023Cash and investments of $492.5 million as of June 30
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Inve
Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes" With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetesResults demonstrate a hypercortisolism prevalence rate of 24 percent in this patient population MENLO PARK, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medic
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously
SVB Securities initiated coverage of Corcept Therapeutics with a rating of Market Perform and set a new price target of $25.00
Piper Sandler initiated coverage of Corcept Therapeutics with a rating of Overweight and set a new price target of $27.00
Jefferies downgraded Corcept Therapeutics from Buy to Hold and set a new price target of $22.00 from $35.00 previously
Truist downgraded Corcept Therapeutics from Buy to Hold and set a new price target of $30.00
Jefferies upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $35.00 from $21.00 previously
Canaccord Genuity resumed coverage of Corcept Therapeutics with a rating of Buy and set a new price target of $34.00 from $30.00 previously
Canaccord Genuity initiated coverage of Corcept Therapeutics with a rating of Buy and set a new price target of $30.00
Truist initiated coverage of Corcept Therapeutics with a rating of Buy and set a new price target of $30.00
HC Wainwright & Co. reiterated coverage of Corcept Therapeutics with a rating of Buy and set a new price target of $29.00 from $32.00 previously